Besides the treatment itself, the timing of chemotherapy given to cancer patients can be important to the success of the treatment.

More people die of lung cancer each year than any other kind of cancer. The survival rate among women, however, is better than men — and the reasons aren't exactly clear.

Lung cancer is the leading cause of cancer-related death in the US. Advanced lung cancers have spread to other areas of the body and are extremely tough to beat. An experimental therapy may be a game changer.

In 2011, the US Food and Drug Administration fast-tracked the approval of Xalkori (crizotinib) to treat a specific type of non-small cell lung cancer (NSCLC). Since its approval, side effects have been discovered.

Though obesity can increase the risk of developing many diseases, the link between obesity and cancer outcomes is still not clear.

Lung cancer isn’t a single disease. Changes in genes produce different versions of lung cancer — the most common cancer in the US. Now there's a new medication designed to treat one specific type of lung cancer.

Changes in genes are at the heart of many cancers. One gene mutation shows up in about 10 percent of lung cancers. That gene is known as the epidermal growth factor receptor (EGFR).

Does race enter the equation on who is treated and who isn't treated for cancer? According to a recent study, there are racial differences in how lung cancer is treated.

You may have heard of HER2-positive breast cancer. You may not know that this gene can also play a role in lung cancer. And anti-HER2 medications may be useful in treating the world’s most common cancer.

In the cancer world, a protein called Hsp90 is a bad actor. It helps a number of different cancers survive and thrive. An experimental medication may become Hsp90’s worst nightmare.